Skip to Main content Skip to Navigation
New interface
Journal articles

A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice

Abstract : Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of SARS-CoV-2 that acts as a highly effective antigen. A construct encoding the RBD of the Delta variant elicits robust neutralizing antibody response, and also provides protective immunity against the Delta variant in a widely used transgenic mouse model. We ultimately find that the proposed mRNA RBD nanoparticle-based vaccine provides a flexible platform for rapid development and will likely be of great value in combatting current and future SARS-CoV-2 variants of concern.
Document type :
Journal articles
Complete list of metadata

https://hal-pasteur.archives-ouvertes.fr/pasteur-03854887
Contributor : Xavier MONTAGUTELLI Connect in order to contact the contributor
Submitted on : Wednesday, November 16, 2022 - 10:01:27 AM
Last modification on : Friday, December 2, 2022 - 9:54:12 AM

File

Brandys-2022-A mRNA Vaccine En...
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

Citation

Pascal Brandys, Xavier Montagutelli, Irena Merenkova, Güliz T Barut, Volker Thiel, et al.. A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. Frontiers in Immunology, 2022, 13, pp.912898. ⟨10.3389/fimmu.2022.912898⟩. ⟨pasteur-03854887⟩

Share

Metrics

Record views

0

Files downloads

0